Cargando…

SYST-09 IMPACT OF END-STAGE RENAL DISEASE AND CONCOMITANT DIALYSIS ON THE EFFICACY OF IMMUNOTHERAPY IN BRAIN METASTASES PATIENTS: A PROPENSITY-MATCHED SURVIVAL ANALYSIS

INTRODUCTION: Mounting evidence demonstrates the therapeutic promise of immunotherapies (ITs) for brain metastases (BM). However, there is concern that stringent eligibility criteria in these clinical studies have selected against patients with comorbid conditions. As a result, it remains unclear if...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baroz, Angel, Bhanja, Debarati, Stahl, Caleb, Wilding, Hannah, Mansouri, Alireza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354167/ http://dx.doi.org/10.1093/noajnl/vdac078.088

Ejemplares similares

SYST-08 SURVIVAL ANALYSIS OF METASTATIC MELANOMA PATIENTS WITH BRAIN METASTASIS USING SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)
por: Stahl, Caleb, et al.
Publicado: (2022)

SDPS-39 AN UPDATED VALIDATION OF PREDICTIVE ALGORITHMS FOR BRAIN METASTASES IN NON-SMALL CELL LUNG CANCER: SYSTEMATIC REVIEW AND INDEPENDENT COHORTVALIDATION ANALYSIS
por: Wilding, Hannah, et al.
Publicado: (2023)

Photodynamic Therapy for Glioblastoma: Illuminating the Path toward Clinical Applicability
por: Bhanja, Debarati, et al.
Publicado: (2023)

SYST-05 OPTIMIZING HER2-TARGETED THERAPIES (TT) FOR BREAST CANCER (BC) LEPTOMENINGEAL METASTASES (LM): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Lazaratos, Anna-Maria, et al.
Publicado: (2022)

Syst
por: Vialettes, H
Publicado: (1971)

SYST-11 PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM
por: Chen, Zhongping, et al.
Publicado: (2022)

SYST-12 D2C7 CAR: A NOVEL CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOMA AND BRAIN METASTASES
por: Wilkinson, Daniel, et al.
Publicado: (2022)

RADI-09. Clinical factors associated with death after radiotherapy for brain metastases
por: Natesan, Divya, et al.
Publicado: (2021)

MMAP-09 CHARACTERISTICS CORRELATING WITH SURVIVAL IN PATIENTS TREATED FOR LARGE BRAIN METASTASES
por: Gutierrez-Valencia, Enrique, et al.
Publicado: (2022)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

SYST-07 WINDOW-OF-OPPORTUNITY STUDY OF ONC201 IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND THALAMIC GLIOMA
por: Odia, Yazmin, et al.
Publicado: (2022)

SYST-03 INCIDENCE AND SURVIVAL OF PATIENTS WITH INTRACRANIAL METASTATIC DISEASE AND ERBB2-POSITIVE GASTROINTESTINAL CANCERS: A RETROSPECTIVE COHORT STUDY
por: Sherman, Madison, et al.
Publicado: (2022)

Emergent immunotherapy approaches for brain metastases
por: Wang, Jianbo, et al.
Publicado: (2021)

SYST-31 PROBIOTIC DELIVERY TO ORTHOTOPIC GLIOBLASTOMA MULTIFORME MODELS AS AN IMMUNOTHERAPY
por: Windemuth, Sophia, et al.
Publicado: (2023)

SYST-10 CSNO2012001 STUDY: A PHASE III TRIAL ON ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY WITH OR WITHOUT INTERFERON-ALPHA IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS
por: Chen, Zhongping, et al.
Publicado: (2022)

SYST-02 PHASE ⅡB CLINICAL TRIAL OF NEOADJUVANT CHEMOTHERAPY REVERSING GLIOMA STEM CELLS CHEMORESISTANCE IN NEWLY DIAGNOSED GBM WITH MGMT PROMOTER UNMETHYLATION
por: Dong, Jun, et al.
Publicado: (2022)

BSCI-09. Multiomic single cell analysis reveals emerging principles of tumor immune microenvironment inherent to NSCLC brain metastases
por: Wen, Lei, et al.
Publicado: (2021)

NEIM-04 LEVERAGING NOVEL NEUROIMAGING TECHNIQUES TO LINK BRAIN METASTASES AND LOCAL GENE EXPRESSION
por: Germann, Jurgen, et al.
Publicado: (2022)

The SysteMHC Atlas project
por: Shao, Wenguang, et al.
Publicado: (2018)

SYST-01 MULTI-INSTITUTIONAL RANDOMIZED TRIAL COMPARING CANCER STEM CELL-TARGETED VS PHYSICIAN-CHOICE TREATMENTS IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS (NCT03632135)
por: Sengupta, Soma, et al.
Publicado: (2022)

BSCI-02 CSF PROTEOMICS AS A MINIMALLY-INVASIVE STRATEGY FOR DISTINGUISHING BRAIN METASTASES FROM OTHER PRIMARY BRAIN MALIGNANCIES
por: Mansouri, Alireza, et al.
Publicado: (2022)

SYST-04 PRELIMINARY REPORT OF A CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICIENCY OF NEOADJUVANT CAMRELIZUMAB AND APATINIB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS: A PROSPECTIVE, PHASE II, SINGLE-ARM STUDY
por: Lin, Fuhua, et al.
Publicado: (2022)

The LHCb RICH Syste: Detector Performance
por: Matteuzzi, C
Publicado: (2013)

SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis
por: Lerner, Emily, et al.
Publicado: (2021)

DDRE-09. THERAPEUTIC TARGETING OF PURINE METABOLISM IN DIPG
por: Mersich, Ian, et al.
Publicado: (2021)

SYST-05 BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS
por: Lorrey, Selena, et al.
Publicado: (2023)

THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES
por: Lauko, Adam, et al.
Publicado: (2019)

CBMS-09 Intercellular communication at glioblastoma stem cell niches
por: Hide, Takuichiro, et al.
Publicado: (2020)

Feature set expansion for the SysteMA software
por: Kirchner, Davide
Publicado: (2014)

SYST-08 ROLE OF THE MICROBIOME IN BRAIN TUMORS
por: Omer, Mohammed
Publicado: (2023)

32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES
por: Galldiks, Norbert, et al.
Publicado: (2020)

BT-09 Anhidrosis in neurohypophyseal germinoma treated with CBDCA and VP-16
por: Adachi, Koji, et al.
Publicado: (2020)

CS-09 Extra-parenchymal (Peripheral) Atypical Teratoid / Rhabdoid Tumors
por: Oka, Hidehiro, et al.
Publicado: (2020)

ETMM-09 TARGETING GLIOBLASTOMA MULTIFORME METABOLISM AT THE INVASIVE TUMOR FRONT
por: Garcia, Joseph H, et al.
Publicado: (2021)

BIMG-09. GLUTAMINE AND GLYCINE BY MR SPECTROSCOPY IDENTIFY AGGRESSIVE GLIOMAS
por: Choi, Changho, et al.
Publicado: (2021)

SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132)
por: Faye, Mame Daro, et al.
Publicado: (2021)

MMAP-10 ADVERSE RADIATION EFFECT AFTER STEREOTACTIC RADIOSURGERY AND IMMUNOTHERAPY/TARGETED THERAPY FOR MELANOMA BRAIN METASTASES
por: Phuong, Christina, et al.
Publicado: (2022)

Impact of initial dialysis modality on mortality: a propensity-matched study
por: Waldum-Grevbo, Bård, et al.
Publicado: (2015)

Association of Low-Grade Glioma Diagnosis and Management Approach with Mental Health Disorders: A MarketScan Analysis 2005–2014
por: Bhanja, Debarati, et al.
Publicado: (2022)

SURG-11. Surgery for control of brain metastases after prior checkpoint inhibitor immunotherapy: a single-center series
por: Morshed, Ramin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vt7ciib4ujff5ssu43bir01d94